363 related articles for article (PubMed ID: 15734947)
21. [Diagnostic scintigraphy and effectiveness of 131I radioiodine therapy in differentiated thyroid carcinoma (DTC)].
Bałdys-Waligórska A; Buziak-Bereza M; Huszno B; Wilczak A
Endokrynol Pol; 2006; 57(4):380-5. PubMed ID: 17006840
[TBL] [Abstract][Full Text] [Related]
22. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
[TBL] [Abstract][Full Text] [Related]
23. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
24. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
25. The role of total thyroidectomy in the management of differentiated thyroid cancer.
Stephenson BM; Wheeler MH; Clark OH
Curr Opin Gen Surg; 1994; ():53-9. PubMed ID: 7584009
[TBL] [Abstract][Full Text] [Related]
26. [Differentiated thyroid gland carcinoma in a scintigraphically hot thyroid nodule: diagnosis and interdisciplinary therapeutic management].
Stahl A; Hess U; Harms J; Zwicknagl M; Langhammer H
Wien Klin Wochenschr; 2002 Jun; 114(10-11):410-4. PubMed ID: 12708097
[TBL] [Abstract][Full Text] [Related]
27. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
Díez JJ; Grande E; Iglesias P
Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
29. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
30. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
Mäenpää H
Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
[TBL] [Abstract][Full Text] [Related]
31. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
[TBL] [Abstract][Full Text] [Related]
32. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
Morris LF; Waxman AD; Braunstein GD
J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
34. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
Lin JD; Chao TC; Huang MJ; Weng HF; Tzen KY
Am J Clin Oncol; 1998 Feb; 21(1):77-81. PubMed ID: 9499265
[TBL] [Abstract][Full Text] [Related]
35. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
36. [Primary hyperparathyroidism in patients treated for non-medullary thyroid carcinoma].
Rubello D; Pagetta C; Pelizzo MR; Casara D
Minerva Endocrinol; 2001 Mar; 26(1):31-4. PubMed ID: 11323565
[TBL] [Abstract][Full Text] [Related]
37. False-positive findings on (131)I whole-body scans because of posttraumatic superficial scabs.
Regalbuto C; Buscema M; Arena S; Vigneri R; Squatrito S; Pezzino V
J Nucl Med; 2002 Feb; 43(2):207-9. PubMed ID: 11850486
[TBL] [Abstract][Full Text] [Related]
38. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
39. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori M; Luster M
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):821-8. PubMed ID: 20186542
[No Abstract] [Full Text] [Related]
40. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
